165669-13-6

Usage

Uses

Used in Pharmaceutical Industry:
3-Chloro-1H-indol-7-amine is utilized as an intermediate in the synthesis of various pharmaceuticals and organic compounds. Its potential biological and pharmacological activities contribute to its use in developing anticancer and antiviral drugs.
Used in Medicinal Chemistry Research:
3-CHLORO-1H-INDOL-7-AMINE is employed as a versatile chemical in medicinal chemistry due to its potential as an antioxidant and radical scavenger, which can be beneficial in the development of treatments for various diseases and conditions.

Upstream product

• 165669-14-7 7-nitro-3-chloro-1H-indole 
• 6960-42-5 7-nitro-1H-indole 

Downstream Products

• 418811-67-3 7-benzyloxy-4-(3-chloroindol-7-ylamino)-6-methoxyquinazoline 
• 945396-44-1 N'-(3-chloro-1H-indol-7-yl)-N-(3-methylsulfonylphenyl)pyrimidine-2,4-diamine 
• 165668-51-9 4-Carbamoyl-N-(3-chloro-1H-indole-7-yl)benzenesulfonamide 
• 165668-25-7 4-Amino-N-(3-chloro-1H-indole-7-yl)benzenesulfonamide 
• 165668-32-6 N-(3-Chloro-1H-indole-7-yl)-4-cyanobenzenesulfonamide 
• 165668-24-6 N-(3-chloro-7-indolyl)-4-nitrobenzenesulfonamide 

Relevant academic research and scientific papers

COMPOUNDS AND USES THEREOF

The present disclosure features compounds useful for the treatment of BAF complex-related disorders.

Integrin expression inhibitors

The present invention provides an integrin expression inhibitor, and an agent for treating arterial sclerosis, psoriasis, cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases, an anticoagulant, or a cancer metastasis suppressor on the basis of an integrin inhibitory action. Namely, it provides an integrin expression inhibitor comprising, as an active ingredient, a sulfonamide compound represented by the following formula (I), a pharmacologically acceptable salt thereof or a hydrate of them. In the formula, B means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated; K means a single bond, —CH═CH— or —(CR4bR5b)mb— (wherein R4b and R5b are the same as or different from each other and each means hydrogen atom or a C1-C4 alkyl group; and mb means an integer of 1 or 2); R1 means hydrogen atom or a C1-C6 alkyl group; Z means a single bond or —CO—NH—; and R means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated, respectively.

Synthesis and biological evaluation of N-(7-indolyl)-3-pyridinesulfonamide derivatives as potent antitumor agents.

We herein report the synthesis and antitumor activity of E7070 analogues containing a 3-pyridinesulfonamide moiety. E7070 was selected from our sulfonamide-based compound collections, currently undergoing Phase II clinical trials because of its tolerable toxicity profile and some antitumor responses in the Phase I setting. Of the analogues examined, ER-35745, a 6-amino-3-pyridinesulfonamide derivative, demonstrated significant oral efficacy against the HCT116 human colon carcinoma xenograft in nude mice.

Array-based structure and gene expression relationship study of antitumor sulfonamides including N-[2-[(4-hydroxyphenyl) amino]-3-pyridinyl] -4-methoxybenzenesulfonamide and N-(3-chloro-7-indolyl)-1,4-benzenedisulfonamide

Compounds from sulfonamide-focused libraries have been evaluated in cell-based antitumor screens using the COMPARE analysis with a panel of 39 human cancer cell lines and flow cytometric cell cycle analysis. Thus far, 2 (N-[2-[(4-hydroxyphenyl)amino]-3pyr

Lactam inhibitors of factor Xa and method

Lactam inhibitors are provided which have the structure including pharmaceutically acceptable salts thereof and all stereoisomers thereof, and prodrug esters thereof, wherein n is 1 to 5; and and R1, R2, R3, R4, R5 , R6, R7, R8, R9, R10, R10a, 1011 and R12 are as defined herein. These compounds are inhibitors of Factor Xa and thus are useful as anticoagulants. A method for treating cardiovascular diseases associated with thromboses is also provided.

Discovery of novel antitumor sulfonamides targeting G1 phase of the cell cycle

Described herein is the discovery of a novel series of antitumor sulfonamides targeting G1 phase of the cell cycle. Cell cycle control in G1 phase has attracted considerable attention in recent cancer research, because many of the important proteins invol